Please use this identifier to cite or link to this item:
Title: Delivering high value therapies in COPD: the secret is in the marketing
Authors: Ashdown, Helen
Steiner, Michael
First Published: 25-Apr-2019
Publisher: European Respiratory Society
Citation: European Respiratory Journal, 2019, 53: 1900215
Abstract: There are a wide range of therapies now available for people suffering with chronic obstructive pulmonary disease (COPD), both pharmacological and non-pharmacological [1]. However, there has been recent recognition that non-pharmacological approaches (for example smoking cessation and pulmonary rehabilitation) deliver the highest value in terms of patient benefit in relation to cost [2]. It is also evident that the provision of high value therapies in clinical practice is frequently sub-optimal, as illustrated in figure 1 summarising data from a recent, comprehensive primary care audit of COPD care in Wales [3]. In healthcare systems such as Australia and the UK, where 90% of healthcare is delivered in primary care [4], there is now a need to investigate how best to implement such high value interventions in primary care.
DOI Link: 10.1183/13993003.00215-2019
ISSN: 0903-1936
Embargo on file until: 25-Apr-2020
Version: Post-print
Status: Peer-reviewed
Type: Journal Article
Rights: Copyright © 2019, European Respiratory Society. Deposited with reference to the publisher’s open access archiving policy. (
Description: The file associated with this record is under embargo until 12 months after publication, in accordance with the publisher's self-archiving policy. The full text may be available through the publisher links provided above.
Appears in Collections:Published Articles, Dept. of Infection, Immunity and Inflammation

Files in This Item:
File Description SizeFormat 
ERJ+editorial+final+V3.pdfPost-review (final submitted author manuscript)166.87 kBAdobe PDFView/Open

Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.